探讨 HERV-K（HML-2）在癌症中的影响及治疗干预的前景。
Exploring HERV-K (HML-2) Influence in Cancer and Prospects for Therapeutic Interventions.
机构信息
OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, s/n, 4200-450 Porto, Portugal.
CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
出版信息
Int J Mol Sci. 2023 Sep 27;24(19):14631. doi: 10.3390/ijms241914631.
This review investigates the intricate role of human endogenous retroviruses (HERVs) in cancer development and progression, explicitly focusing on HERV-K (HML-2). This paper sheds light on the latest research advancements and potential treatment strategies by examining the historical context of HERVs and their involvement in critical biological processes such as embryonic development, immune response, and disease progression. This review covers computational modeling for drug-target binding assessment, systems biology modeling for simulating HERV-K viral cargo dynamics, and using antiviral drugs to combat HERV-induced diseases. The findings presented in this review contribute to our understanding of HERV-mediated disease mechanisms and provide insights into future therapeutic approaches. They emphasize why HERV-K holds significant promise as a biomarker and a target.
本综述探讨了人类内源性逆转录病毒（HERV）在癌症发展和进展中的复杂作用，特别关注 HERV-K（HML-2）。本文通过研究 HERV 的历史背景及其在胚胎发育、免疫反应和疾病进展等关键生物学过程中的参与，揭示了最新的研究进展和潜在的治疗策略。本综述涵盖了用于药物靶标结合评估的计算建模、用于模拟 HERV-K 病毒载体动力学的系统生物学建模，以及使用抗病毒药物来对抗 HERV 诱导的疾病。本综述中提出的研究结果有助于我们理解 HERV 介导的疾病机制，并为未来的治疗方法提供了思路。它们强调了 HERV-K 作为生物标志物和靶标具有重要意义的原因。
Zotero 插件